What You Should Know:
– The investment will allow Syapse to expand its artificial intelligence and machine learning capabilities, making it more efficient to uncover meaningful insights from real-world oncology data.
Syapse, a San Francisco, CA-based real-world evidence company accelerating the delivery of precision medicine through the Syapse Learning Health NetworkTM, today announced the closing of a $35M led by an affiliate of Innovatus Capital Partners, LLC (Innovatus), with participation from existing investors including Ally Bridge Group, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics, and Social Capital.
Improving Cancer Care Through Global Data Sharing
Founded in 2008, Syapse’s oncology software platform enables oncologists to practice precision medicine consistently across large health systems. The Syapse Data Sharing Network puts the power of real-world evidence in the hands of oncologists, enabling physicians to view treatments and outcomes for patients across the country and use this information to improve treatment decisions for their own patients.
Learning Health Network Expansion
Syapse has expanded its Learning Health Network by partnering with some of the nation’s leading community health systems to support precision medicine strategies that are directed at improving clinical outcomes, reducing costs and enhancing the experience of their patients. In addition, Syapse has added life sciences partnerships with established biopharmaceutical companies. Recently, Syapse presented research at American Society of Clinical Oncology (ASCO) focused on how the use of machine learning on real-world data can be used to power precision medicine solutions.
“We are extremely pleased that Innovatus supports our mission to marry technology and real-world data to provide high-quality healthcare to cancer patients by transforming provider-driven data into actionable insights for health systems and life sciences,” said Ken Tarkoff, chief executive officer of Syapse.